There is still time to complete the Immune Deficiency Foundation’s (IDF) first-ever Chronic Granulomatous Disease (CGD) Survey. Please check your inbox and spam/junk folders! We are still hoping to receive completed surveys from people affected by CGD in the IDF community. Participating in the CGD Survey will help increase what is currently known about CGD. […]
Chronic Granulomatous Disease (CGD) is a primary immunodeficiency which may present with infection or inflammation. Unfortunately, many people with CGD go undiagnosed for many years, oten resulting in periods of recurring infections for patients. The Clinical Immunology Society (CIS) has created videos directed towards primary care providers and specialists who may encounter a patient with […]
“The old saying that it takes a village to raise a child is particularly true for a child with a chronic illness, such as Chronic Granulomatous Disease,” says Barbara Meade. Barbara should know–her son Joseph was diagnosed with Chronic Granulomatous Disease (CGD) at the age of two. This was the early 90s, the days before […]
The Chronic Granulomatous Disease (CGD) Survey was emailed today! Please consider offering us a few moments of your time by completing the survey. This study is a collaborative effort with the CGD Association. Developed with immunologists who are experts in primary immunodeficiency diseases, including CGD, the purpose of this survey is to learn more about […]
The Immune Deficiency Foundation (IDF) is excited to launch our very first CGD-specific survey, and we encourage you to participate when the survey is available in the upcoming weeks. Development of the CGD Survey was a collaborative effort—immunologists who are experts in primary immunodeficiency diseases, including CGD, worked with IDF and the CGD Association to […]
Pfizer Inc. is voluntarily recalling RELPAX®(eletriptan hydrobromide) 40 mg tablets, lots AR5407 and CD4565, to the Patient level. Pfizer Inc. initiated this recall because these product lots may not meet Pfizer’s in-house microbiological specification for the potential presence of Genus Pseudomonas and Burkholderia. For additional information, click here.
Today, one in 10 people are living with a rare disease. This week, a new website RAREisCommunity.com was launched for the more than 350 million people around the world who are living with a rare disease, and a place for each unique voice and journey to come together around shared experiences. Resources on the new […]
Summer means travel for many people. Being diagnosed with chronic granulomatous disorder (CGD) doesn’t mean you have to stay home. It is best to consult with your physician if you are traveling, especially if you are traveling abroad, but with a bit of planning you will be on your way. Medication and Supplies Medication […]
IDF 2019 National Conference Join the Immune Deficiency Foundation (IDF) at our biennial National Conference for people with primary immunodeficiencies (PI) and their families—offering strategies for coping with PI, providing opportunities to meet other facing similar journeys, and presenting the latest science-based information about PI diagnoses and treatments. The 2019 National Conference will be held […]
The National Organization for Rare Disorders (NORD) has expanded their assistance available to the Chronic Granulomatous Disease (CGD) community to assist individuals with CGD with limited resources to pay for some related expenses. To learn more about this program, click here. La Organización Nacional de Enfermedades Raras (NORD, por sus siglas en inglés) ha ampliado […]
Children with Chronic Granulomatous Disease (CGD) often seem healthy at birth but develop severe infections in infancy and during early childhood. This was the case of Erik Mainville of Interlachen, Florida. When Erik was born, he appeared to be a normal, healthy baby. In those early years, however, he remembers many infections, pneumonia episodes, and […]
Last week, to honor Rare Disease Day, thousands of people around the globe took time to advocate and raise awareness about rare diseases and their impact on patients’ lives. With only five percent of all rare diseases having an FDA approved treatment, there is tremendous unmet need that requires innovative collaborations and continued conversations across the healthcare […]